2-(3,4,5-trifluorophenyl)-3H-thieno[3,2-d]pyrimidin-4-one | 884534-71-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并嘧啶酮衍生物
• 英文名称: 2-(3,4,5-trifluorophenyl)-3H-thieno[3,2-d]pyrimidin-4-one
• CAS: 884534-71-8
• 化学式: C₁₂H₅F₃N₂OS
• 分子量: 282.246
• InChiKey: NXHGVNBLQIYMNW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  69.7
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Aromatic-Ring-Fused Pyrimidine Derivative
  申请人：Yonetoku Yasuhiro

  公开号：US20070249587A1

  公开（公告）日：2007-10-25

  There are provided novel pyrimidine derivatives which has been fused with an aromatic heterocycle selected from thiophene, thiazole and pyridine or pharmaceutically acceptable salts thereof; and a pharmaceutical composition comprising said compound as an active ingredient. These compounds exhibit excellent promoting activity on insulin secretion and activity against hyperglycemia. Hence, the pharmaceutical compositions comprising such compounds as active ingredients, based on these actions, are useful for treating and/or preventing insulin-dependent diabetes (type 1 diabetes), non-insulin-dependent diabetes (type 2 diabetes), insulin-resistant diseases, obesity, and the like.

  提供了一种新颖的嘧啶衍生物，其已与从噻吩、噻唑和吡啶中选择的芳香杂环或其药学上可接受的盐融合；以及包含该化合物作为活性成分的制药组合物。这些化合物表现出促进胰岛素分泌和对高血糖的活性的优异作用。因此，基于这些作用，包含这些化合物作为活性成分的制药组合物对于治疗和/或预防胰岛素依赖性糖尿病（1型糖尿病）、非胰岛素依赖性糖尿病（2型糖尿病）、胰岛素抵抗性疾病、肥胖症等是有用的。
• AROMATIC-RING-FUSED PYRIMIDINE DERIVATIVE
  申请人：Astellas Pharma Inc.

  公开号：EP1806347A1

  公开（公告）日：2007-07-11

  There are provided novel pyrimidine derivatives which has been fused with an aromatic heterocycle selected from thiophene, thiazole and pyridine or pharmaceutically acceptable salts thereof; and a pharmaceutical composition comprising said compound as an active ingredient. These compounds exhibit excellent promoting activity on insulin secretion and activity against hyperglycemia. Hence, the pharmaceutical compositions comprising such compounds as active ingredients, based on these actions, are useful for treating and/or preventing insulin-dependent diabetes (type 1 diabetes), non-insulin-dependent diabetes (type 2 diabetes), insulin-resistant diseases, obesity, and the like.

  本研究提供了新型嘧啶衍生物，该衍生物与选自噻吩、噻唑和吡啶的芳香杂环或其药学上可接受的盐融合；还提供了以上述化合物为活性成分的药物组合物。这些化合物对胰岛素分泌和高血糖具有良好的促进作用。因此，以这些化合物为活性成分的药物组合物可用于治疗和/或预防胰岛素依赖型糖尿病（1 型糖尿病）、非胰岛素依赖型糖尿病（2 型糖尿病）、胰岛素抵抗性疾病、肥胖症等。
• US7557112B2
  申请人：——

  公开号：US7557112B2

  公开（公告）日：2009-07-07